Ms Ya Huei C Chu, in Summit, NJ - General Acute Care Hospital

Ms Ya Huei C Chu, is a General Acute Care Hospital based in Summit, New Jersey. Ms Ya Huei C Chu is licensed to practice in New Jersey (license number 28RI01930000) and her current practice location is 99 Beauvoir Ave, Summit, New Jersey. She can be reached at her office (for appointments etc.) via phone at (908) 522-2222.

NPI number for Ms Ya Huei C Chu is 1063781524 and her current mailing address is 50 Rockledge Dr, Livingston, New Jersey. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1063781524.

Contact Information

	Ms Ya Huei C Chu,
	99 Beauvoir Ave, Summit, NJ 07901-3533
	(908) 522-2222
	Not Available

Healthcare Provider's Profile

Full Name	Ms Ya Huei C Chu
Gender	Female
Speciality	General Acute Care Hospital
Location	99 Beauvoir Ave, Summit, New Jersey
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1063781524
Provider Enumeration Date: 12/29/2011
Last Update Date: 12/29/2011

Medical Identifiers

Medical identifiers for Ms Ya Huei C Chu such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1063781524	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
183500000X	Pharmacist	33235 (New York)	Secondary
282N00000X	General Acute Care Hospital	28RI01930000 (New Jersey)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Ms Ya Huei C Chu is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Ms Ya Huei C Chu, 50 Rockledge Dr, Livingston, NJ 07039-1902 Ph: (973) 882-5645	Ms Ya Huei C Chu, 99 Beauvoir Ave, Summit, NJ 07901-3533 Ph: (908) 522-2222

News Archive

Study demonstrates cardiovascular safety of weight loss drug

A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI 61 trial presented today in a Hot Line Session at ESC Congress and published in the New England Journal of Medicine.

Researchers launch clinical trial to assess therapeutic drug monitoring for patients with inflammatory diseases

New research presented at ACR Convergence, the American College Rheumatology's annual meeting, showed that patients with rheumatic diseases whose infliximab treatment was individually assessed and adjusted with a new strategy called therapeutic drug monitoring did not achieve remission at higher rates compared to those who received standard care.

Brivaracetam drug shows no added benefit for epilepsy

Brivaracetam (trade name: Briviact) has been approved since January 2016 as add-on therapy for adolescents from the age of 16 years and adults with epileptic seizures. The German Institute for Quality and Efficiency in Health Care now examined in an early benefit assessment whether this drug offers an added benefit for patients in comparison with the appropriate comparator therapy.

Magnetized molecules help monitor breast cancer

A study published in the journal Proceedings of the National Academy of Sciences reports on a novel type of scanning which uses magnetized molecules to visualize active areas within a breast tumor specifically. This marks the first successful attempt to demonstrate the role of this type of scanning in the field of breast cancer monitoring.

Sofosbuvir in combination with ribavirin/peginterferon achieves highest SVR rates in GT-3 HCV patients

Results presented today at The International Liver Congress 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.

Ms Ya Huei C Chu, - Pharmacist in Summit, NJ